Recruitment is currently underway for the MATTERHORN phase III study (NCT04592913) of neoadjuvant durvalumab (anti-PDL-1) or placebo and FLOT chemotherapy followed by adjuvant durvalumab or placebo monotherapy in patients with resectable GC/GEJC, with results expected in 2025 [61]. The gene discussed is CD274; the disease is gastric cancer.